Published in Int J Radiat Oncol Biol Phys on April 12, 2011
Radiosurgery and Avastin for Recurrent Malignant Gliomas | NCT01017250
Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res (2014) 1.12
Recent advancements in multimodality treatment of gliomas. Future Oncol (2011) 1.02
Dexamethasone alleviates tumor-associated brain damage and angiogenesis. PLoS One (2014) 0.97
Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach? Ann Transl Med (2016) 0.83
Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. J Oncol (2011) 0.81
The biology of radiosurgery and its clinical applications for brain tumors. Neuro Oncol (2014) 0.81
Radiosurgery for high-grade glioma. Surg Neurol Int (2012) 0.81
Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Radiat Oncol (2014) 0.79
Salvage radiosurgery for selected patients with recurrent malignant gliomas. Biomed Res Int (2014) 0.79
Recurrent malignant gliomas. Semin Radiat Oncol (2014) 0.79
Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Oncotarget (2016) 0.78
Stereotactic Radiosurgery for Glioblastoma. Cureus (2015) 0.78
External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma. Expert Rev Anticancer Ther (2016) 0.78
Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience. Neurosurgery (2016) 0.77
Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma. Neurooncol Pract (2014) 0.76
Sense and sensibility to early combine bevacizumab to radiation treatment of brain metastasis: reply to Lou and Sperduto. Ann Transl Med (2016) 0.75
The evolving roles and controversies of radiotherapy in the treatment of glioblastoma. J Med Radiat Sci (2016) 0.75
New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics (2017) 0.75
The radiosurgery fractionation quandary: single fraction or hypofractionation? Neuro Oncol (2017) 0.75
Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas. Rep Pract Oncol Radiother (2015) 0.75
Re-irradiation alternatives for recurrent high-grade glioma. Oncol Lett (2016) 0.75
Intracavitary moderator balloon combined with (252)Cf brachytherapy and boron neutron capture therapy, improving dosimetry in brain tumour and infiltrations. Br J Radiol (2015) 0.75
MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma. J Neurooncol (2017) 0.75
Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys (2017) 0.75
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol (1999) 8.69
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 8.50
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell (2004) 6.99
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer (2008) 2.89
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol (2006) 2.33
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol (2010) 2.30
Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys (2007) 2.10
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07
A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer (1991) 1.93
The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol (2008) 1.93
Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys (2007) 1.82
Anticancer strategies involving the vasculature. Nat Rev Clin Oncol (2009) 1.82
Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res (2003) 1.82
Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery (1987) 1.49
Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer (2005) 1.46
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol (2009) 1.37
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res (2008) 1.35
Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys (1994) 1.34
Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol (2003) 1.30
The value of reoperation for recurrent glioblastoma. Can J Surg (1993) 1.26
Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys (1999) 1.25
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology (2004) 1.16
Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer (2008) 1.11
The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neurooncol (2009) 1.11
Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol (2009) 1.11
Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol (2005) 1.11
Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol (1995) 1.08
Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer (1994) 0.92
The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest (1996) 0.92
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer (2002) 3.23
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol (2007) 3.19
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology (2005) 3.01
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2007) 2.99
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol (2008) 2.81
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Impact of PhD training on scholarship in a neurosurgical career. J Neurosurg (2013) 2.59
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol (2006) 2.58
Recent advances in the treatment of malignant astrocytoma. J Clin Oncol (2006) 2.55
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys (2011) 2.54
Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys (2008) 2.45
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol (2011) 2.38
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol (2004) 2.30
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res (2002) 2.23
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery (2012) 2.19
Structure determination of the seven-helix transmembrane receptor sensory rhodopsin II by solution NMR spectroscopy. Nat Struct Mol Biol (2010) 2.17
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys (2012) 2.12
Proteomic and immunologic analyses of brain tumor exosomes. FASEB J (2008) 2.11
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol (2008) 2.07
Intensity-modulated radiation therapy for anal cancer. Oncology (Williston Park) (2009) 2.07
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2004. A 61-year-old man with rectal bleeding and a 2-cm mass in the rectum. N Engl J Med (2004) 2.01
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Molecularly targeted therapy for malignant glioma. Cancer (2007) 1.96
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol (2005) 1.85
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res (2003) 1.85
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther (2008) 1.84
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol (2012) 1.84
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res (2008) 1.80
How much radiation is the chemotherapy worth in advanced head and neck cancer? Int J Radiat Oncol Biol Phys (2007) 1.78
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery (2007) 1.74
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007) 1.74
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther (2009) 1.67
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther (2005) 1.66
US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol (2009) 1.65
Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol (2007) 1.65
Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg (2010) 1.65
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol (2009) 1.65
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res (2011) 1.64
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res (2009) 1.64
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med (2007) 1.64
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2005) 1.63